linjc16/ctgov huggingface dataset:
RCT of Mailed Brochure to Boost Adherence to Screening Colonoscopy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect of a mailed educational brochure on adherence to referral for screening colonoscopy. The comparison (or control) group receives no mailer, which is usual care.

Official Title
-----------------
Randomized Controlled Trial of a Mailed Brochure to Increase Adherence to Referrals for Screening Colonoscopy

Conditions
-----------------
Colonoscopy, Mass Screening

Intervention / Treatment
-----------------
* Behavioral: Mailed educational brochure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Referrals for screening colonoscopy; Asymptomatic; age>=50 Exclusion Criteria: Referrals for diagnostic colonoscopy

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Mailed educational brochure|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of adherence to screening colonoscopy referral within at least three months of receipt of referral. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
screening colonoscopy, adherence
Blood Types and Erectile Dysfunction

Study Overview
=================
Brief Summary
-----------------
The researchers aimed to investigate the relationship between ABO blood types and erectile dysfunction.

Detailed Description
-----------------
This retrospective study is done in Ordu university Hospital among patients who administered to urology polyclinic between April 2013 and April 2014. Sexually active 102 patients whose blood types were known were included in this study. While 56 patients had sexual intercourse problems 46 had not and this group was taken as a control group. Individuals who had a sexual partner and whose sexual intercourse were continuing unproblematic ally were accepted as normal. Individuals who had not have sexual intercourse though having a sexual partner or unable to maintain the intercourse were accepted to have sexual dysfunction. Patients' sexual function was evaluated via the İEFF-5 questioning form. In the same session the patients' blood types were also recorded and their İEFF-5 (Erectile Function International Evaluation Form) symptom scores were compared with their blood types.

Official Title
-----------------
The Relation Between ABO Blood Types and Erectile Dysfunction

Conditions
-----------------
Erectile Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male, person who have sexual intercourse Exclusion Criteria: Female, who have no sexual intercourse
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relationship between erectile dysfunction and blood group antigens |  | 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood Group Antigens, erectile dysfunction
The Effect of Preoperative Anxiety on Duration and Efficacy of Motor and Sensory Block in Spinal Anesthesia

Study Overview
=================
Brief Summary
-----------------
Spinal anaesthesia results in blockade of sympathetic efferent neurones. Patients with higher baseline sympathetic activation have been shown to have more marked hypotension after spinal anaesthesia. Anxiety causes generalized sympathetic activation. It was aimed to find the effect of preoperative anxiety on the duration and efficacy of neuraxial anaesthesia.

Official Title
-----------------
The Effect of Preoperative Anxiety on Duration and Efficacy of Motor and Sensory Block in Spinal Anesthesia

Conditions
-----------------
Anxiety

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged between 18 and 55 years. ASA I-II BMI 18-25 Exclusion Criteria: Major surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| State-Trait Anxiety Inventory questionnaire | State-Trait Anxiety Inventory questionnaire is a direct psychological assessment of preoperative anxiety. | 20-30 minutes. |
Incidence of Unresectable Cases of Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
Objective : to calculate the incidence of unresectable cases of cervical cancer in gyne-oncology unit of Alexandria university hospital and to indentify its relation to pathological types, grading and lymph vascular space invasion. Patients and methods: 70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion

Official Title
-----------------
Incidence of Unresectable Cases of Cervical Cancer in Gyne-oncology Unit of Alexandria University Hospital and Its Relation to Pathological Types, Grading and Lymph Vascular Space Invasion

Conditions
-----------------
Cervical Cancer

Intervention / Treatment
-----------------
* Diagnostic Test: clinical and radiological staging, pathological types, grading and lymphovascular space invasion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cervical cancer Exclusion Criteria: none -
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: clinical and radiological staging, pathological types, grading and lymphovascular space invasion|70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical and radiological staging | 70 cases of cervical cancer diagnosed by biopsy taking and histopathological examination will be included in the study, clinicoradiological staging was done to all cases to calculate the incidence of unresectable cases and to indentify its relation to pathological types, grading and lymph vascular space invasion. | 10 days |
Physical Exercise Versus Rosiglitazone in CAD and Prediabetes

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to prospectively assess the relative benefits of either treatment with rosiglitazone or physical exercise on endothelial function in patients with impaired fasting glucose or impaired glucose tolerance and coronary artery disease (CAD).

Official Title
-----------------
Effects of Physical Exercise Versus Rosiglitazone on Endothelial Function in Coronary Artery Disease Patients With Prediabetes

Conditions
-----------------
Impaired Glucose Tolerance

Intervention / Treatment
-----------------
* Drug: rosiglitazone
* Behavioral: physical exercise
* Other: control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: impaired fasting glucose or impaired glucose tolerance angiographic evidence of coronary artery disease Exclusion Criteria: diabetes mellitus type I or II preexisting antidiabetic medication unstable angina indication for coronary bypass surgery significant left main disease myocardial infarction within preceding 3 months ejection fraction < 40% significant heart valve disease severe metabolic disorders severe disorders in lipoprotein metabolism thyroid disorders alcohol or drug abuse pregnancy participation in another trial

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: rosiglitazone<br>* tablets 4 mg daily<br>* Other names: Avandia (GlaxoSmithKline);|
| Active Comparator: 2<br>physical exercise | Behavioral: physical exercise<br>* stationary bike 5-6 times a week<br>|
| No Intervention: 3<br>control | Other: control<br>* control without intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| between-group difference in flow-mediated dilation of the brachial artery |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| relative effects of treatment on parameters of - glucose metabolism - inflammatory plasma markers - markers of endothelial function - cellular markers in muscle and fat biopsies |  | 6 months |
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This observational study will assess the median time of treatment duration and the safety of Avastin (bevacizumab) as first line treatment in patients with metastatic breast cancer. Data will be collected for approximately 24 months.

Official Title
-----------------
Avastin in First Line Metastatic or Recurrent Breast Cancer. Retrospective Phase IV Study

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Drug: Bevacizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin Exclusion Criteria: Patients not willing or unable to signed written consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bevacizumab<br>Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed. | Drug: Bevacizumab<br>* Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to Disease Progression (TDP) | Time to disease progression was defined as the time interval between first-line treatment onset and investigator-assessed disease progression. Disease progression was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. | Up to a maximum of 36.4 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Treatment Duration: Number of Bevacizumab Cycles | Bevacizumab treatment duration in routine clinical practice was measured by the number of bevacizumab treatment cycles. | Up to a maximum of 36.4 months |
Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This Situation

Study Overview
=================
Brief Summary
-----------------
HIV virus is an etiologic agent of ( AIDS ) immunodeficiency syndrome . It is known that the estimated rate of transfer from mother to baby is 25% to 45%, pregnancy rate is 5-10%, pregnancy rate is 15-20% and in lactation period is 5-10%. Risk factors; maternal viral load, breastfeeding, vaginal birth, and prematurity. Although there is a high rate of false positivity in prenatal screening in our country, one of the factors affecting this is the number of pregnancies.

Official Title
-----------------
Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This Situation

Conditions
-----------------
HIV Seropositivity, Acquired Immunodeficiency Syndrome, Pregnancy, High Risk

Intervention / Treatment
-----------------
* Other: Anti HIV Seropositive Pregnant Women


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anti HIV seropositive Pregnant Women Exclusion Criteria: Anti HIV seronegative Pregnant Women
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Anti HIV Seropositive Pregnant Women|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The effect of the number of pregnancies on Anti HIV false positivity rate |  | 5 years |
Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese Adults

Study Overview
=================
Brief Summary
-----------------
Multi-center, multiple-dose, randomized, double-blind, three-arm, placebo-controlled study of fixed-dose repeated oral dosing for 30 days of 10 mg and 30 mg MP-101 and placebo in obese subjects.

Official Title
-----------------
A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults.

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Drug: oleoyl-estrone (MP-101)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is willing and able to provide signed informed consent. Subject is a male and is between 18-60 years of age. Subject is obese as defined as a BMI of 40 - 55. Subject is reasonably healthy and have a reasonably acceptable medical history Subject has a stable weight for the past 30 days per subject report. Subject who has at least one factor of the metabolic Subject exhibits stable behavior patterns with regard to smoking and exercise Subject can read, speak and write the English language and agrees to follow study procedures. Exclusion Criteria: Subjects who have received any investigational medication within 3 months prior to administration of study drug Subjects with confirmed positive results of UDS or Alcohol Subjects who are unwilling to return to the clinical research center on specified days during the treatment periods. Subjects who have taken exclusionary medication Subjects with any clinically significant laboratory abnormality or illness which, in the opinion of the Investigator, would contraindicate study participation Subjects who have a history of testing positive for Hepatitis B virus, Hepatitis C virus, or HIV. Subject has been involved in a formal or informal (self-imposed) diet regimen within the last 30 days. Subject has a confirmed diagnosis or history of cancer, with the exception of nonmelanoma skin cancer. Subject is otherwise unsuitable for the study, in the opinion of the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: oleoyl-estrone (MP-101)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety and tolerability |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the preliminary efficacy |  |  |
Endoscopic Myotomy of the Lower Esophageal Sphincter for Achalasia

Study Overview
=================
Brief Summary
-----------------
This is a study of the safety and efficacy of a new surgical procedure using endoscopic instruments and a tunneling technique to reach the LES for dissection. We hypothesize that this technique provides an incisionless, less invasive option with similar functional outcome compared to standard Heller myotomy.

Detailed Description
-----------------
By the endoscopic creation of an esophageal submucosal tunnel the inner circular muscle layer can be easily visualized. In contrast to conventional Heller myotomy, the dissection of only the inner circular esophageal muscle layer leaves the outer longitudinal muscle layer intact. Thereby, post-interventional reflux disease should be avoided.

Official Title
-----------------
Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter for Achalasia

Conditions
-----------------
Achalasia

Intervention / Treatment
-----------------
* Procedure: Endoscopic Myotomy
* Procedure: Endoscopic Myotomy for treatment of achalasia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to undergo general anesthesia Age > 18 yrs. of age and < 85 yrs. of age Ability to give informed consent Candidate for elective Heller myotomy Exclusion Criteria: Previous mediastinal or esophageal surgery Contraindications for esophagogastroduodenoscopy BMI > 45

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Endoscopic Myotomy<br> | Procedure: Endoscopic Myotomy<br>* Patients will receive the surgical procedure described in the summary (POEM).<br>* Other names: POEM;Procedure: Endoscopic Myotomy for treatment of achalasia<br>* Surgical procedure<br>* Other names: POEM;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improved quality of life as defined by survey pre and post surgery | patients diagnosed with achalasia will be given a quality of life survey before surgery and again six months after surgery. | six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Negative pH test | Patients will be required to have 24 hour pH testing after surgery. | six months | 
| Bleeding | recorded blood loss will be taken during surgery. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Achalasia
Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to collect data to support decisions made by BioFire regarding assay development, panel composition, and intended use for the final FilmArray FI reagent pouch. The study will utilize whole blood and/or plasma obtained from pediatric patients under 3 years of age that present with acute fever.

Official Title
-----------------
Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel

Conditions
-----------------
Acute Fever

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: under age of 3 has fever with no obvious focal infection written informed parental permission Exclusion Criteria: parent/legal guardian unable to provide permission participation determined by a physician to be detrimental to patient health

Ages Eligible for Study
-----------------
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Utility of multiplexed testing for pathogens in pediatric patients with acute fever |  | 15 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Epidemiology of pathogens in pediatric patients with acute fever |  | 15 Months |